Millennium: The Takeda Oncology Company today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for VELCADE, which expands the label to include long-term (median follow-up 36.7 months) overall survival (OS) data from the landmark VISTA trial and provides specific dosing recommendations for patients with hepatic impairment. The ... Santarus, Inc., a specialty biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved Schering-Plough HealthCare Products, Inc.’s, New Drug Application (NDA) for ZEGERID OTC™ Capsules (omeprazole/sodium bicarbonate) with a dosage strength of 20 mg of omeprazole for over-the-counter (OTC) treatment of frequent heartburn. Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for ABILIFY® (aripiprazole) for the treatment of irritability associated with autistic disorder in pediatric patients ages 6 to 17 years, including symptoms of aggression towards others, deliberate self ...

Shire to Present Important Study Findings on its ADHD Treatments at a Major ... Reuters "We are excited to provide new scientific data on our ADHD portfolio, which includes the newest FDA-approved ADHD treatment INTUNIV; Vyvanse, the first ... Shire plc to Present Scientific Data on ADHD Treatments TransWorldNews (press release) all 52 news articles »

Shire to Present Important Study Findings on its ADHD Treatments at a Major ... Earthtimes (press release) "We are excited to provide new scientific data on our ADHD portfolio, which includes the newest FDA-approved ADHD treatment INTUNIV; Vyvanse, the first ... and more »